An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Abroad (travel likely)RecruitingPHASE3

Conditions

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
Contact: Study coordinator (Xianjun Yu) · yuxianjun@fudanpci.org · +86-021-64175590
Contact: Principal Investigator (Xianjun Yu)
Tianjin University Cancer Institute and Hospital, Tianjin, Tianjin Municipality, China
Contact: Study coordinator (Jihui Hao) · herenrh@163.com · 022-23353454
Contact: Principal Investigator (Jihui Hao)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

GEP-NET · Gastroenteropancreatic Neuroendocrine Tumor · Gastroenteropancreatic Neuroendocrine Tumor Disease

Abroad (travel likely)RecruitingPHASE3

Phoenix, United States · Duarte, United States

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

Neuroendocrine Tumors Unresectable · Neuroendocrine Tumor Metastatic · Gastroenteropancreatic Neuroendocrine Tumor

Abroad (travel likely)RecruitingPHASE1, PHASE2

Jacksonville, United States · Miami, United States